检索临床试验

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1311在晚期实体瘤患者中的安全性和耐受性.

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, 法尼基转移酶抑制剂(FTI), 作为单一疗法和联合疗法, 成年晚期实体瘤患者.

该研究尚未在ClinicalTrials上注册.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• 如果您需要临床试验方面的帮助.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• 如果您需要临床试验方面的帮助.gov registration for a non-oncology study, please contact the 监管事务办公室.

该研究尚未在ClinicalTrials上注册.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• 如果您需要临床试验方面的帮助.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• 如果您需要临床试验方面的帮助.gov registration for a non-oncology study, please contact the 监管事务办公室.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-3-600 in patients with advanced cancer

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1310在晚期实体瘤患者中的安全性和耐受性.

这项研究是首次在人类身上进行, 第一阶段, 非盲, 多中心研究评估安全性, 耐受性, 药代动力学(PK), 药效学(PD), JANX007单药治疗成人转移性去势抵抗性前列腺癌(mCRPC)的初步疗效.

这项临床试验的目的是测试CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

它旨在回答的主要问题是:

• 评估CPO301增加剂量的安全性和耐受性，并确定研究第二部分(A部分)的使用剂量。
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• To evaluate how quickly CPO301 is metabolized by the body (药物动力学 or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• 评价药物的初步疗效
• To correlate preliminary efficacy with mutations in a biomarker called EGFR

参与者将:

• 提供书面知情同意
• Undergo screening tests to ensure they are eligible for study treatment
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, 基于参与者在治疗中的表现
• Be followed for progression every 3 months for up to 2 years

OPTIMUM是一项旨在比较超高分辨率经直肠微超声(microUS)和多参数MRI (mpMRI)/US融合指导前列腺活检的能力的研究.

这是人类首次(FIH) I/II期, 跨国公司, 多中心, 非盲 study of HB-201 single vector therapy and HB-201 & HB-202双载体治疗HPV 16+确诊癌症患者包括两部分:I期剂量递增和II期剂量扩大.

这项II期试验评估了阿帕鲁胺与图像引导立体定向放射治疗(SBRT)联合治疗前列腺癌患者的疗效. Prostate cancer usually needs the hormone testosterone to grow. Apalutamide is a hormone therapy that blocks the effect of testosterone on prostate tumor cells. This may help stop the growth of tumor cells that need testosterone to grow. Image-guided SBRT is a standard treatment for some types of 前列腺癌. This treatment combines imaging of cancer within the body, with the delivery of therapeutic radiation doses produced on a linear accelerator machine. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. 阿帕鲁胺联合影像引导的SBRT可能会增加前列腺癌患者获得极低前列腺特异性抗原应答的机会, 哪个是疾病治愈的早期预测指标.

本研究的目的是评价其安全性, 耐受性, 以及XmAb808联合派姆单抗在选定的晚期实体肿瘤患者中静脉(IV)给药的药代动力学，并确定XmAb808的最低安全和生物有效/推荐剂量(RD)和时间表.

一项评估ARV-766单独口服或与阿比特龙联合用于转移性前列腺癌男性的安全性和有效性的1/2期研究.

Study CP-MGC018-03 is an 非盲, two-part, Phase 2 study. 该研究的第一部分将招募转移性去势抵抗性前列腺癌(mCRPC)患者，这些患者此前曾接受过一种雄激素受体轴靶向治疗(ARAT)。. ARAT包括阿比特龙、恩杂鲁胺或阿帕鲁胺. Participants may have received up to 1 prior docetaxel-containing regimen, 但没有其他化疗药物.

这部分研究将在两个实验组(2)中评估伏布拉米单抗多氨基嗪(MGC018)的疗效和耐受性.每4周0 mg/kg [Q4W].7 mg/kg Q4W) . 大约100名参与者将以1:1的比例随机分配.

Part 2 of the study will enroll participants with locally advanced or metastatic squamous cell carcinoma (SCC) of the anus, 黑素瘤, 头颈部鳞状细胞癌, 鳞状非小细胞肺癌, 小细胞肺癌(SCLC). 对于晚期或转移性疾病，参与者必须进行至少1次标准化疗. Participants will receive vobramitamab docarmazine at a dose of 2.每4周7毫克/公斤. 第2部分最多可招收200名参与者.

在这两个部分, vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered for up to 26 cycles, 大约2年, 直到达到停止治疗的标准. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, 核磁共振成像, 骨扫描, 以及前列腺特异性抗原(PSA)血液测试. Routine examinations and blood tests will be performed and evaluated by the study doctor.

这是第一次人体试验, 阶段1 b / 1, 多中心, 非盲, STK-012在选定的晚期实体瘤患者中作为单药和联合派姆单抗的剂量递增研究.

来描述安全性, 耐受性, 药物动力学, 药效学, and 初步抗肿瘤活性 of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, 食管鳞癌, 肾细胞癌, and human papilloma virus associated head and neck squamous cell carcinoma.

一个first-in-human, 非盲, 多中心, 第一阶段 study of KZR-261 designed to assess the safety and 耐受性, 初步抗肿瘤活性, KZR-261的药代动力学(PK), 以及确定推荐的2期剂量(RP2D). The study comprises a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (黑素瘤/uveal 黑素瘤, 间皮瘤, 结肠直肠癌, 前列腺癌, 和“肿瘤”).

本研究将评估capivasertib +多西紫杉醇与安慰剂+多西紫杉醇在转移性去势抵抗性前列腺癌(mCRPC)患者中的疗效和安全性。, all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. 该研究的目的是证明capivasertib联合多西紫杉醇在研究参与者的总生存率方面优于安慰剂联合多西紫杉醇, when overall survival is defined as the time from randomization until the date of death due to any cause.